Skip to main content

Fiscal Wizard · Single-issue tearsheet

EDIT / Jun 21, 2026 Run #7295

EDIT

Editas Medicine, Inc.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Composite verdict

D 40.6 / 100
Gated stand-aside 0 drivers · 7 gates blocking
Stand aside Setup or conviction grade does not support a directional trade.

Industry rank 109th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: volatile range

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Mixed

40.6 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Free Cash Flow Yield 0
Revenue Growth (YoY) 100
Days Sales Outstanding 0
EV/Sales 75
Return on Capital Employed 25

Technicals Unscored

/ 100

Stand aside — active guards gated the directional signals that fired. · 43 signals shown.

Risk Gates

7 blocking 5 caution

7 guards active, 42 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Debt-to-Equity Blocking

High debt-to-equity blocks bullish signals — leverage risk.

LT Debt-to-Equity Blocking

High long-term D/E blocks bullish signals — structural-leverage risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for EDIT.